secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2025-05-09T23:59:59+00:00
Accession:  0001193125-25-116443
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera Q1 net loss $65.6M, cash $775M; unveils oral IRF5 degrader KT-579; STAT6 data June
--------------------------------------------------------------------------------

- Net loss $65.6M (Q1 2025) vs $48.6M (Q1 2024); collab revenue $22.1M incl $20M Sanofi milestone.
- Cash $775M as of Mar 31, 2025; runway extended into H1 2028.
- KT-621 (STAT6) Ph1 SAD/MAD healthy volunteer data due June 2025; BroADen Ph1b in AD started, data 4Q25.
- New oral IRF5 degrader KT-579 unveiled; IND-enabling ongoing, Phase 1 expected early 2026.
- Strategic decision to not advance KT-295 (TYK2) into clinic; focus on STAT6 and IRF5.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525116443/0001193125-25-116443-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525116443/d27625d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-116443

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer